Navigation Links
Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Date:3/29/2009

ilatory anaerobic threshold (p=0.03). These effects were largely maintained at twelve months as well.

"This subgroup of the less severely impaired patients appeared to demonstrate an overall greater response rate that those in the control group," noted Dr. Alan Kadish, professor, Division of Cardiology, Feinberg School of Medicine, Northwestern University. "We are particularly encouraged by the findings in this subgroup of patients and look forward to focusing on this subgroup in our next study."

Yuval Mika, chief operating officer of Impulse Dynamics, commented, "The data show that CCM therapy has the potential to be an important new therapy for a greatly underserved group of heart failure patients. We have a clear pathway for further studies of CCM in this population which we believe will have favorable outcomes in the near future."

For a complete copy of the study, please contact Erich Sandoval at 917-497-2867 or esandoval@lazarpartners.com.

About Cardiac Contractility Modulation (CCM) Therapy

Cardiac Contractility Modulation is a new treatment for patients with heart failure. Unlike electrical signals delivered by other cardiac devices, such as pacemakers and implantable defibrillators, CCM signals do not initiate a heartbeat. Rather, CCM signals are intended to modify heart cell function in a manner that improves the strength of the heart muscle, therefore potentially enhancing the heart's overall pumping ability.

About the OPTIMIZER System

The OPTIMIZER System is CE Marked and commercially available in Europe and is currently under clinical investigation at major U.S. research and academic facilities. It consists of a pulse generator and conventional pacing leads which deliver the therapy to
'/>"/>

SOURCE Impulse Dynamics (U.S.A.) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
2. New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
3. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
7. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
8. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
11. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors ... BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, ... announced financial results for its first fiscal quarter ... Quarter Highlights and Recent Developments: ... in improving its cost structure, driven by lower ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Array BioPharma ... for the fourth quarter and full year of ... Ron Squarer, Chief Executive Officer of Array, noted, ... Phase 3, are on track for regulatory submissions ... in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... 04, 2007 /PRNewswire/ -- Novagali Pharma, an,emerging ... positive results from the Phase III,clinical study ... (VKC). In this orphan disease, it was ... improved in patients,receiving Vekacia(R). Furthermore, the tolerability ...
... Phase III study of ERBITUX with,chemotherapy in ... primary endpoint of improving overall survival --, ... ImClone,Systems Incorporated and Bristol-Myers Squibb Company announced,today ... of ERBITUX(R) (Cetuximab),combined with platinum-based chemotherapy met ...
Cached Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 9
(Date:8/4/2015)... ... August 04, 2015 , ... Lightning Labels is pleased to ... that will usher in a new standard of sticker and label-making for the ... meet its twin objectives of quality and quantity without compromising the signature lightning-fast ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... analysis for executives and technology professionals in healthcare and technology markets, today announced ... the Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related ...
(Date:8/3/2015)... (PRWEB) , ... August 04, 2015 , ... ... HomeCEUConnection.com announced today an extensive line up of live courses for the month ... more live courses individually or by purchasing a Physical Therapy Flex ...
(Date:8/3/2015)... ... 03, 2015 , ... Zeiter’s Septic now performs septic installations ... and operated business, Zeiter’s Septic has been serving the community for over 20 ... because of their continued training and perseverance to provide their customers with new ...
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number ... according to a new publication released today by the AAMC (Association of American Medical ... graduates over the past three decades, the number of black male applicants to medical ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... men treated with a combination of radiation seed implants ... cured of their disease 15 years// following their treatment, ... Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO. ... at the Seattle Prostate Institute. Doctors wanted to look ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... alleviate symptoms of early-stage Parkinson's disease, and may be ... the brain disorder,// researchers said., ,A neupro patch ... to study its effects on 277 people in Canada ... is designed to convey a drug called rotigotine ...
... Parkinson's appear to increase the risk of heart valve disease, ... disorder of the central nervous system that often impairs motor ... that keep blood flowing in the right direction through the ... blood may not move the way it should., ,The ...
... is the final awakening' - Walter Scott// ... the former president of Iraq, Saddam Hussein, was sent to the ... the fact that he slaughtered 148 fellow countrymen, who were Shias, ... put to use in all societies to wipe out political dissent. ...
... Inner city dwellings were thought to be far cleaner and ... say this is not true- inner cities are a haven// ... and TNS analyzed smoking and disease rates and dietary habits ... The analysis revealed that towns such as Merthyr Tydfil in ...
Cached Medicine News:Health News:'Hooded Horror': Death by Hanging 2Health News:'Hooded Horror': Death by Hanging 3
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
For the quantitative in vitro determination of Total Protein in serum and plasma...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: